VVOS — Vivos Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1716166 ·
Last close
$0.15
Market Cap
$3.00M
52W High
$3.28
52W Low
$0.13
ADV30
24,469,817
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,153,000 | 2,953,000 | -4,825,000 | -5,481,000 | 24,144,000 | 1,774,000 | 28,130,000 |
| Mar 2026 | 5,141,000 | 3,059,000 | -6,615,000 | -7,751,000 | 25,043,000 | 2,110,000 | 26,310,000 |
| Dec 2025 | 3,824,000 | 2,988,000 | -6,382,000 | -6,954,000 | 25,152,000 | 2,029,000 | 26,702,000 |
| Sep 2025 | 6,783,000 | 3,937,000 | -4,734,000 | -5,400,000 | 25,644,000 | 3,087,000 | 23,112,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,477,000
Investing CF
$-7,422,000
Financing CF
$24,667,000
CapEx
$-2,442,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.01
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-133,039,000
Inventory
—
Receivables
$1,769,000
ST Investments
—
EBIT TTM
$-22,596,000
Pretax Income TTM
$-25,118,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,902,000
EBITDA
$-20,763,000
Free Cash Flow
$-8,534,250
Enterprise Value
$15,366,716
Total Cash
$1,774,000
Total Debt
$12,505,000
Shares Out
20,118,023
Trailing EPS
$-1.88
Book Value
$-0.34
ROE
-8585.3%
ROA
-56.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,443,000 | -19,894,000 | -21,230,000 | 25,152,000 | 26,702,000 | -1,490,000 | -15,263,000 |
| Dec 2024 | 15,031,000 | -11,171,000 | -11,136,000 | 15,284,000 | 7,330,000 | 7,954,000 | -12,691,000 |
| Dec 2023 | 13,801,000 | -17,296,000 | -13,583,000 | 10,730,000 | 10,319,000 | 411,000 | -11,946,000 |
| Dec 2022 | 16,024,000 | -25,031,000 | -23,845,000 | 13,720,000 | 8,919,000 | 4,801,000 | -19,587,000 |
TTM Snapshot
Revenues TTM
$19,568,000
NetIncome TTM
$-24,988,000
OpCashFlow TTM
—
Assets (Latest)
$25,043,000
Forward EPS
$-0.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NXL | Nexalin Technology, Inc. | $3.01M | $3.63 | — |
| AMIX | Autonomix Medical, Inc. | $3.02M | $3.11 | — |
| ADGM | Adagio Medical Holdings, Inc. | $2.89M | $0.13 | — |
| ADMT | ADM TRONICS UNLIMITED, INC. | $3.38M | $0.05 | — |
| DROR | Dror Ortho-Design, Inc. | $3.42M | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate
2026-09-29 14:42 · Yahoo
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
2026-09-29 12:45 · Yahoo
Vivos Therapeutics Announces Material Debt Reduction
2026-09-08 12:45 · Yahoo
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
2026-09-01 12:00 · Yahoo
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
2026-08-28 12:45 · Yahoo
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
2026-08-25 12:45 · Yahoo
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts
2026-08-17 11:05 · Yahoo
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
2026-08-14 21:40 · Yahoo
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
2026-08-14 12:45 · Yahoo
Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology
2026-08-05 14:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.